FDA Pulls 16 Unused Generic Drug Approvals
Published Date: 6/3/2026
Notice
Summary
The FDA is officially pulling the plug on 16 generic drug approvals because the companies told them these medicines aren’t being sold anymore. This change kicks in on July 6, 2026, and it won’t stop companies from trying again later if they want. If you’re a drug maker or just curious, this means fewer old approvals cluttering the books and a cleaner, fresher drug list.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 2 costs, 0 mixed.
FDA Withdraws 16 Generic Approvals
The FDA is withdrawing approval of 16 abbreviated new drug applications (ANDAs) at the request of the applicants. This withdrawal takes effect on July 6, 2026 and applies to the entire application and all strengths and dosage forms.
Post-Withdrawal Sales Are Prohibited
After July 6, 2026, introducing into interstate commerce any of the listed products without an approved ANDA violates sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act. Firms that distribute or attempt to market these products without approval would be acting unlawfully.
Existing Inventory May Still Be Dispensed
Drug products listed in the notice that are in inventory on July 6, 2026 may continue to be dispensed until the inventories are depleted or the products reach their expiration dates, whichever occurs first. This allows existing stock at pharmacies or wholesalers to be used up after the approval withdrawal date.
Withdrawals Are Without Prejudice
The FDA states that withdrawal of approval under 21 CFR 314.150(c) is without prejudice to refiling. That means applicants may refile ANDAs later if they choose to pursue approval again.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-11060, Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities-Questions and Answers; Revised Draft Guidance for Industry; Availability
The FDA just released a revised draft guide to help drug and device makers share important cost and coverage info with insurance companies and similar groups. This update clears up how to talk about approved products, unapproved products, and new uses, making it easier for everyone to understand the rules. Companies should send their feedback by August 3, 2026, so the FDA can finalize the guide—potentially speeding up coverage decisions and saving money.
Next: 2026-11063, Proposed Exemption Involving the Abiomed Retirement Savings Plan Located in Danvers, MA
The Abiomed Retirement Savings Plan in Danvers, MA, wants permission to hold special financial rights called contingent value rights (CVRs) and get payments from them. Without this okay, these moves would break some important retirement rules. If approved, the exemption starts retroactively from November 15, 2022, and folks have until July 20, 2026, to share their thoughts or ask for a hearing.